Enterprise Value

5.207B

Cash

2.354B

Avg Qtr Burn

-94.18M

Short % of Float

5.88%

Insider Ownership

0.74%

Institutional Own.

93.23%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
QALSODY™ (Tofersen) Details
Amyotrophic lateral sclerosis

Approved

Update

SPINRAZA Details
Spinal muscular atrophy

Approved

Quarterly sales

Eplontersen (AKCEA-TTR-LRx) Details
Transthyretin amyloidosis

PDUFA

Approval decision

ION363 Details
ALS (Amyotrophic Lateral Sclerosis)

Phase 3

Data readout

Eplontersen (AKCEA-TTR-LRx) Details
Transthyretin Amyloid Cardiomyopathy, Transthyretin amyloidosis

Phase 3

Data readout

IONIS-APOCIII-LRx (Olezarsen) Details
Severe hypertriglyceridemia

Phase 3

Data readout

Phase 3

Data readout

IONIS-APOCIII-LRx (Olezarsen) Details
Familial chylomicronemia syndrome

Phase 3

Data readout

Phase 3

Update

Phase 2/3

Data readout

ION224 Details
Non-alcoholic steatohepatitis

Phase 2b

Data readout

Phase 2b

Update

Phase 2

Data readout

Phase 2

Update

IONIS-AGT-LRx Details
Pulmonary hypertension, Heart failure

Phase 2

Update

Failed

Discontinued

Failed

Discontinued